First preclinical safety biomarkers (7) qualified by the FDA, EMA and PMDA

June 2008 (FDA & EMA), June 2010 (PMDA): C-Path’s PSTC leads novel drug safety effort which yields FDA/EMA/PMDA qualification of new drug tests for kidney safety.